---
title: "Trulicity (dulaglutide) in type 2 diabetes: Clinical trials questions"
description: "Clinical trials questions on Trulicity (dulaglutide) in type 2 diabetes, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Study results, Subgroup results, Long-term results, Comparative studies, and Cardiovascular outcomes. Questions: How quickly does Trulicity lower blood sugar after the first dose? How much does Trulicity lower A1C? Do Trulicity 3 mg and 4.5 mg lower A1C more than 1.5 mg (AWARD-11)? Does Trulicity lower A1C more when baseline A1C is higher (AWARD-11)? 10 further questions follow. 14 questions quoted from 5 sources."
canonical: "https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/clinical-trials"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Trulicity (dulaglutide) in type 2 diabetes: Clinical trials questions

Manufacturer: Eli Lilly and Company  
Prescribing information: [Trulicity](https://uspl.lilly.com/trulicity/trulicity.html#pi)

Questions that apply to every indication of Trulicity are on [Trulicity (dulaglutide), all indications](https://www.evicenter.com/medical-information/trulicity).

## Study results

<a id="trulicity-glucose-after-first-dose"></a>

### How quickly does Trulicity lower blood sugar after the first dose?

Applies to: Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

> “A bar chart shows the fasting serum glucose 48 hours after the first dose of Trulicity.
> For patients on the 0.75 milligram dose of Trulicity (n=11) with a mean baseline FSG of 156.5 mg/dL, the least squares mean change was -28.4 mg/dL.
> For patients on the 1.5 milligram dose of Trulicity (n=9) with a mean baseline FSG of 143.6 mg/dL, the least squares mean change was -35.2 mg/dL.
> For patients given a placebo (n=8) with a mean baseline FSG of 153.0 mg/dL, the least squares mean change was -9.7 mg/dL.
>
> A bar chart shows the 2-hour postprandial serum glucose 48 hours after the first dose of Trulicity.
> For patients on the 0.75 milligram dose of Trulicity (n=11) with a mean baseline PSG of 217.8 mg/dL, the least squares mean change was -46.8 mg/dL.
> For patients on the 1.5 milligram dose of Trulicity (n=9) with a mean baseline PSG of 212.9 mg/dL, the least squares mean change was -66.5 mg/dL
> For patients given a placebo (n=8) with a mean baseline PSG of 227.8 mg/dL, the least squares mean change was -7.1 mg/dL.”

Source: [TRULICITY: How Trulicity Works, MOA & FPG and PPG Reductions | HCP, captured 2026-11-13](https://trulicity.lilly.com/hcp/how-trulicity-works#:~:text=A%20bar%20chart%20shows%20the,mean%20change%20was%20%2D7.1%20mg%2FdL.)

> “These data are from a pharmacodynamics study.
> Data presented are secondary endpoints.”

Source: [TRULICITY: How Trulicity Works, MOA & FPG and PPG Reductions | HCP, captured 2026-11-13](https://trulicity.lilly.com/hcp/how-trulicity-works#:~:text=These%20data%20are%20from%20a,Data%20presented%20are%20secondary%20endpoints.)

> “6-week, multicenter, parallel-design, double-blind, part-randomized, placebo-controlled, multiple-dose, phase 1 study in patients ≥65 years old with type 2 diabetes treated with oral antihyperglycemic medications except sulfonylureas, disaccharidase inhibitors, and meglitinides
> Study arms included placebo (n=8); Trulicity 0.5 mg (n=9), not a marketed dose; Trulicity 0.75 mg (n=11); and Trulicity 1.5 mg (n=9)
> Primary objective was to evaluate the safety and tolerability of Trulicity 0.5 mg, 0.75 mg, and 1.5 mg for 6 weeks; mixed effect linear model; primary objective met
> Data presented are LS mean change from baseline and are secondary endpoints”

Source: [TRULICITY: How Trulicity Works, MOA & FPG and PPG Reductions | HCP, captured 2026-11-13](https://trulicity.lilly.com/hcp/how-trulicity-works#:~:text=6%2Dweek%2C%20multicenter%2C%20parallel%2Ddesign%2C%20double%2Dblind%2C%20part%2Drandomized%2C,baseline%20and%20are%20secondary%20endpoints)

> “The reduction in fasting and postprandial glucose can be observed after a single dose.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=The%20reduction%20in%20fasting%20and,observed%20after%20a%20single%20dose.)

Note: The bar chart description is from the How Trulicity Works page; the study enrolled patients 65 years of age or older, and 0.5 mg is not a marketed dose.

<a id="trulicity-a1c-reduction"></a>

### How much does Trulicity lower A1C?

Applies to: Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

> “In clinical studies, the mean A1C reduction from baseline at primary endpoint was 0.7% to 1.6% for the 0.75 mg dose and 0.8% to 1.6% for the 1.5 mg dose. In a clinical study, the mean A1C reduction from baseline was 1.5% for the 1.5 mg dose (active control); 1.6% for the 3.0 mg dose; and 1.8% for the 4.5 mg dose.<sup>1,2</sup>”

Source: [TRULICITY: Clinical Trials: Lowereing A1C, Weight Change & CV Data | HCP, captured 2026-11-13](https://trulicity.lilly.com/hcp/efficacy-weight#:~:text=In%20clinical%20studies%2C%20the%20mean,1.8%25%20for%20the%204.5%20mg)

> “<sup>*</sup>Trulicity 3.0 mg was not statistically significant vs Trulicity 1.5 mg on A1C change from baseline.”

Source: [TRULICITY: Clinical Trials: Lowereing A1C, Weight Change & CV Data | HCP, captured 2026-11-13](https://trulicity.lilly.com/hcp/efficacy-weight#:~:text=3.0%20mg%20was%20not%20statistically%20significant%20vs%20Trulicity%201.5%20mg%20on%20A1C%20change%20from%20baseline.,-A%20prespecified%20subgroup)

> “52-week, randomized, active-controlled (Trulicity 1.5 mg), double-blind phase 3 study of adult patients with type 2 diabetes treated with metformin ≥1500 mg/day.”

Source: [TRULICITY: Clinical Trials: Lowereing A1C, Weight Change & CV Data | HCP, captured 2026-11-13](https://trulicity.lilly.com/hcp/efficacy-weight#:~:text=52%2Dweek%2C%20randomized%2C%20active%2Dcontrolled%20%28Trulicity%201.5,treated%20with%20metformin%20%E2%89%A51500%20mg%2Fday.)

> “Primary objective was to demonstrate superiority of Trulicity 3.0 mg and/or Trulicity 4.5 mg vs Trulicity 1.5 mg on A1C change from baseline at 36 weeks (-1.6% and -1.8% vs -1.5%, respectively; P<.001 for Trulicity 4.5 mg vs Trulicity 1.5 mg); primary objective met for Trulicity 4.5 mg, but not for 3.0 mg.”

Source: [TRULICITY: Clinical Trials: Lowereing A1C, Weight Change & CV Data | HCP, captured 2026-11-13](https://trulicity.lilly.com/hcp/efficacy-weight#:~:text=Primary%20objective%20was%20to%20demonstrate,but%20not%20for%203.0%20mg.)

Note: Values are mean changes from baseline within each Trulicity group. The 3.0 mg and 4.5 mg values are from AWARD-11 at 36 weeks, described in the last two passages; differences from placebo or active comparators are in the trial-specific questions.

<a id="trulicity-award11-higher-doses"></a>

### Do Trulicity 3 mg and 4.5 mg lower A1C more than 1.5 mg (AWARD-11)?

Applies to: Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

> “In this parallel-arm, double-blind trial with primary endpoint at 36 weeks, a total of 1842 adult patients were randomized 1:1:1 to TRULICITY 1.5 mg, TRULICITY 3 mg, or TRULICITY 4.5 mg once weekly, all as add-on to metformin (NCT03495102).”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=In%20this%20parallel%2Darm%2C%20double%2Dblind%20trial,as%20add%2Don%20to%20metformin%20%28NCT03495102%29.)

> “Following randomization, all patients received TRULICITY 0.75 mg once weekly. The dose was increased every 4 weeks to the next higher dose until the patients reached their assigned dose (1.5 mg, 3 mg, or 4.5 mg). Patients were to remain on the assigned study dose for the duration of the trial.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=Following%20randomization%2C%20all%20patients%20received,the%20duration%20of%20the%20trial.)

> “At 36 weeks, treatment with TRULICITY 4.5 mg resulted in a statistically significant reduction in HbA1c and in body weight compared to TRULICITY 1.5 mg (Table 6 and Figure 4).”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=At%2036%20weeks%2C%20treatment%20with,%28Table%206%20and%20Figure%204%29.)

> “Table 6. Results at Week 36 of TRULICITY 1.5 mg Compared to 3 mg and 4.5 mg as Add-On to Metformin in Adult Patients with Type 2 Diabetes Mellitusa
>
> Abbreviations: HbA1c = hemoglobin A1c
>
>
>
>
> a Intent-to-treat population. At Week 36, primary efficacy was missing for 7%, 7%, and 6% of individuals treated with TRULICITY 1.5 mg, TRULICITY 3 mg, and TRULICITY 4.5 mg, respectively.
>
>
>
>
> b Least-squares mean adjusted for baseline value and other stratification factors. Missing data were imputed using multiple imputation.
>
>
>
>
> c Patients with missing HbA1c data at Week 36 were considered as not achieving HbA1c target.
>
>
>
>
> ^ p=0.0001 for superiority compared to TRULICITY 1.5 mg, overall type I error controlled.
>
>
>
>
> ^^ p<0.0001 for superiority compared to TRULICITY 1.5 mg, overall type I error controlled.
>
>
> 	36-Week Primary Time Point
> TRULICITY
> 1.5 mg	TRULICITY
> 3 mg	TRULICITY
> 4.5 mg
> Intent-to-Treat (ITT) Population (N)	612	616	614
> HbA1c (%) (Mean)
> Baseline	8.6	8.6	8.6
> Change from baselineb	-1.5	-1.6	-1.8
> Difference from 1.5 mgb (95% CI)		-0.1 (-0.2, 0.0)	-0.2 (-0.4, -0.1) ^
> Percentage of patients HbA1c <7.0% c	50	56	62
> Fasting Serum Glucose (mg/dL) (Mean)
> Baseline	185	184	183
> Change from baselineb	-45	-46	-51
> Difference from 1.5 mgb (95% CI)		- 2 (-7, 3)	-6 (-11, -2)
> Body Weight (kg) (Mean)
> Baseline	95.5	96.3	95.4
> Change from baselineb	-3.0	-3.8	-4.6
> Difference from 1.5 mgb (95% CI)		-0.9 (-1.4, -0.4)	-1.6 (-2.2, -1.1) ^^”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=Table%206.%20Results%20at%20Week,%2D1.6%20%28%2D2.2%2C%20%2D1.1%29)

> “<sup>*</sup>Trulicity 3.0 mg was not statistically significant vs Trulicity 1.5 mg on A1C change from baseline at 36 weeks.”

Source: [TRULICITY: Clinical Trials: Lowereing A1C, Weight Change & CV Data | HCP, captured 2026-11-13](https://trulicity.lilly.com/hcp/efficacy-weight#:~:text=3.0%20mg%20was%20not%20statistically,from%20baseline%20at%2036%20weeks.)

Note: Table 6 columns are TRULICITY 1.5 mg, 3 mg, and 4.5 mg, in that order. The Trulicity HCP site identifies this dose-ranging trial as AWARD-11.

<a id="trulicity-kidney-disease-trial"></a>

### Does Trulicity lower A1C in moderate to severe chronic kidney disease?

Applies to: Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

> “In this open-label comparator trial (double-blind with respect to TRULICITY dose assignment) with primary endpoint at 26 weeks, a total of 576 adult patients with type 2 diabetes were randomized and treated to compare TRULICITY 0.75 mg and 1.5 mg with insulin glargine (NCT01621178).”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=Chronic%20Kidney%20Disease-,In%20this%20open%2Dlabel%20comparator%20trial%20%28double%2Dblind%20with%20respect%20to%20TRULICITY,mg%20with%20insulin%20glargine%20%28NCT01621178%29.)

> “At baseline, overall mean eGFR was 38 mL/min/1.73 m2, 30% of patients had eGFR <30 mL/min/1.73 m2, and 45% of patients had macroalbuminuria. Patients on over 70 units/day of basal insulin were excluded from the trial.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=At%20baseline%2C%20overall%20mean%20eGFR,were%20excluded%20from%20the%20trial.)

> “Treatment with TRULICITY 0.75 mg and 1.5 mg once weekly resulted in a reduction in HbA1c at 26-weeks from baseline. The difference in observed effect size between TRULICITY 0.75 mg and 1.5 mg, respectively, and glargine in this trial excluded the pre-specified non-inferiority margin of 0.4%. Mean fasting plasma glucose increased in the TRULICITY arms (Table 13).”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=from%20the%20trial.-,Treatment%20with%20TRULICITY%200.75%20mg%20and%201.5%20mg%20once%20weekly,the%20TRULICITY%20arms%20%28Table%2013%29.)

> “Table 13: Results at Week 26 of TRULICITY Compared to Insulin Glargine, Both in Combination with Insulin Lispro, in Patients with Moderate to Severe Chronic Kidney Disease in Adult Patients with Type 2 Diabetes Mellitusa
>
> Abbreviation: HbA1c = hemoglobin A1c
>
>
>
>
> a Intent-to-treat population (all randomized and treated patients) was used in the analysis regardless of discontinuation of study drug or initiation of rescue therapy. At Week 26, primary efficacy was missing for 12%, 15%, and 9% of individuals randomized to and treated with TRULICITY 0.75 mg, TRULICITY 1.5 mg, and insulin glargine, respectively. Missing data were imputed using multiple imputation within treatment group.
>
>
>
>
> b Least-squares (LS) mean from ANCOVA pattern mixture model adjusted for baseline value and other stratification factors.
>
>
> 	26-Week Primary Time Point
> TRULICITY
> 0.75 mg	TRULICITY
> 1.5 mg	Insulin Glargine
> Intent-to-Treat Population (N)	190	192	194
> HbA1c (%) (Mean)
> Baseline	8.6	8.6	8.6
> Change from baselineb	-0.9	-1.0	-1.0
> Difference from insulin glargineb (95% CI)	0.0 (-0.2, 0.3)	-0.1 (-0.3, 0.2)	
> Percentage of patients HbA1c <8.0%	73	75	74
> Fasting Serum Glucose (mg/dL) (Mean)
> Baseline	167	161	170
> Change from baselineb	6	14	-23
> Difference from insulin glargineb (95% CI)	30 (16, 43)	37 (24, 50)”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=Table%2013%3A%20Results%20at%20Week,37%20%2824%2C%2050%29)

Note: Table 13 columns are TRULICITY 0.75 mg, 1.5 mg, and insulin glargine, in that order; all arms also received insulin lispro.

<a id="trulicity-weight-change"></a>

### How much weight do adults lose on Trulicity?

Applies to: Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

> “Trulicity is not indicated for weight loss.”

Source: [TRULICITY: Trulicity & Weight Loss | HCP, captured 2026-11-13](https://trulicity.lilly.com/hcp/efficacy-weight/weight-loss-dosing#:~:text=Trulicity%20is%20not%20indicated%20for%20weight%20loss.,-In%20clinical%20trials)

> “In clinical trials with primary endpoint ranging from 26 to 52 weeks, weight change was a secondary endpoint. Mean weight change from baseline ranged from +0.4 lb to -10.1 lb for 0.75 mg dose to 4.5 mg dose respectively.<sup>3,4</sup>”

Source: [TRULICITY: Trulicity & Weight Loss | HCP, captured 2026-11-13](https://trulicity.lilly.com/hcp/efficacy-weight/weight-loss-dosing#:~:text=In%20clinical%20trials%20with%20primary,dose%20to%204.5%20mg%20dose)

> “For Trulicity 1.5 milligrams, mean weight change from baseline at 36 weeks was -6.6 pounds.
>
> For Trulicity 3.0 milligrams, mean weight change from baseline at 36 weeks was -8.4 pounds.
>
> For Trulicity 4.5 milligrams, mean weight change from baseline at 36 weeks was -10.1 pounds.”

Source: [TRULICITY: Trulicity & Weight Loss | HCP, captured 2026-11-13](https://trulicity.lilly.com/hcp/efficacy-weight/weight-loss-dosing#:~:text=For%20Trulicity%201.5%20milligrams%2C%20mean,36%20weeks%20was%20%2D10.1%20pounds.)

> “<sup>*</sup>Trulicity 3.0 mg was not statistically significant vs Trulicity 1.5 mg on weight change from baseline based on the multiplicity testing approach.
> On average, patients experienced weight loss; however, some patients did not lose weight.”

Source: [TRULICITY: Trulicity & Weight Loss | HCP, captured 2026-11-13](https://trulicity.lilly.com/hcp/efficacy-weight/weight-loss-dosing#:~:text=3.0%20mg%20was%20not%20statistically,patients%20did%20not%20lose%20weight.)

> “52-week, randomized, active-controlled (Trulicity 1.5 mg), double-blind phase 3 study of adult patients with type 2 diabetes treated with metformin ≥1500 mg/day”

Source: [TRULICITY: Trulicity & Weight Loss | HCP, captured 2026-11-13](https://trulicity.lilly.com/hcp/efficacy-weight/weight-loss-dosing#:~:text=52%2Dweek%2C%20randomized%2C%20active%2Dcontrolled%20%28Trulicity%201.5,treated%20with%20metformin%20%E2%89%A51500%20mg%2Fday)

Note: The 36-week values are from AWARD-11, whose study description on the weight page of the Trulicity HCP site is the last passage.

## Subgroup results

<a id="trulicity-award11-baseline-a1c"></a>

### Does Trulicity lower A1C more when baseline A1C is higher (AWARD-11)?

Applies to: Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

> “A prespecified subgroup analysis was conducted by baseline A1C <8.5% and ≥8.5% for change from baseline in A1C at 36 weeks. The mean change from baseline in A1C in the subgroup with baseline A1C<8.5% was -1.2% for Trulicity 1.5 mg and -1.4% for Trulicity 3 mg and 4.5 mg. In the subgroup with baseline A1C≥8.5%, the mean change in A1C was -1.9%, -2.0% and -2.3% for Trulicity 1.5 mg, 3 mg and 4.5 mg respectively.<sup>3,4</sup>”

Source: [TRULICITY: Clinical Trials: Lowereing A1C, Weight Change & CV Data | HCP, captured 2026-11-13](https://trulicity.lilly.com/hcp/efficacy-weight#:~:text=A%20prespecified%20subgroup%20analysis%20was,mg%2C%203%20mg%20and%204.5%20mg)

> “The diagram shows the results of an exploratory post hoc subgroup analysis by baseline A1C range in adults with type 2 diabetes taking Trulicity. The results are presented in a bar chart that is separated by mean baseline A1C.
>
> For patients who have an A1C baseline less than 8% receiving Trulicity 1.5 milligram (n=138), the mean reduction in A1C was 1% point from 7.6% to 6.6%. For patients receiving Trulicity 3.0 milligrams (n=148), the mean reduction in A1C was 1.2% points from 7.5% to 6.4%. For patients receiving Trulicity 4.5 milligrams (n=140), the mean reduction was 1.2% points from 7.6% to 6.4%.
>
> For patients who have an A1C baseline between 8% and 9% receiving Trulicity 1.5 milligram (n=209), the mean reduction in A1C was 1.4% points from 8.4% to 7.0%. For patients receiving Trulicity 3.0 milligrams (n=216), the mean reduction in A1C was 1.6% points from 8.4% to 6.8%. For patients receiving Trulicity 4.5 milligrams (n=228), the mean reduction was 1.8% points from 8.4% to 6.6%.
>
> For patients who have an A1C baseline between 9% and 10% receiving Trulicity 1.5 milligram (n=125), the mean reduction in A1C was 2.1% points from 9.4% to 7.3%. For patients receiving Trulicity 3.0 milligrams (n=101), the mean reduction in A1C was 2.2% points from 9.4% to 7.2%. For patients receiving Trulicity 4.5 milligrams (n=99), the mean reduction was 2.3% points from 9.4% to 7.1%.
>
> For patients who have an A1C baseline greater than 10% receiving Trulicity 1.5 milligram (n=47), the mean reduction in A1C was 2.2% points from 10.4% to 8.3%. For patients receiving Trulicity 3.0 milligrams (n=55), the mean reduction in A1C was 2.5% points from 10.5% to 8.0%. For patients receiving Trulicity 4.5 milligrams (n=53), the mean reduction was 3.2% points from 10.4% to 7.2%.”

Source: [TRULICITY: Clinical Trials: Lowereing A1C, Weight Change & CV Data | HCP, captured 2026-11-13](https://trulicity.lilly.com/hcp/efficacy-weight#:~:text=The%20diagram%20shows%20the%20results,points%20from%2010.4%25%20to%207.2%25.)

> “The data could represent chance findings as there is no control for type 1 error.”

Source: [TRULICITY: Clinical Trials: Lowereing A1C, Weight Change & CV Data | HCP, captured 2026-11-13](https://trulicity.lilly.com/hcp/efficacy-weight#:~:text=The%20data%20could%20represent%20chance,control%20for%20type%201%20error.)

> “The data presented are not intended to make clinical comparisons between baseline A1C subgroups within or across products at any time point.”

Source: [TRULICITY: Clinical Trials: Lowereing A1C, Weight Change & CV Data | HCP, captured 2026-11-13](https://trulicity.lilly.com/hcp/efficacy-weight#:~:text=The%20data%20presented%20are%20not,products%20at%20any%20time%20point.)

Note: The first passage reports a prespecified subgroup analysis; the second describes a separate exploratory post hoc analysis by narrower baseline A1C ranges.

## Long-term results

<a id="trulicity-award11-52-weeks"></a>

### Do Trulicity A1C reductions last 52 weeks (AWARD-11)?

Applies to: Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

> “The mean observed A1C values from the AWARD-11 clinical trial were compared between three doses of Trulicity: 1.5 milligrams (n=612), 3.0 milligrams (n=616), and 4.5 milligrams (n=614). Collectively, these patients had a mean baseline A1C of 8.6%. At 52 weeks, the final mean A1C values were 7.0% for patients receiving 1.5 milligrams, 6.9% for the 3.0 milligrams group, and 6.8% for the 4.5 milligrams group.”

Source: [TRULICITY: Clinical Trials: Lowereing A1C, Weight Change & CV Data | HCP, captured 2026-11-13](https://trulicity.lilly.com/hcp/efficacy-weight#:~:text=The%20mean%20observed%20A1C%20values,for%20the%204.5%20milligrams%20group.)

> “Data represent unadjusted mean observed values (no imputation) irrespective of study treatment discontinuation”

Source: [TRULICITY: Clinical Trials: Lowereing A1C, Weight Change & CV Data | HCP, captured 2026-11-13](https://trulicity.lilly.com/hcp/efficacy-weight#:~:text=Data%20represent%20unadjusted%20mean%20observed,irrespective%20of%20study%20treatment%20discontinuation)

> “52-week A1C change from baseline results are exploratory.”

Source: [TRULICITY: Clinical Trials: Lowereing A1C, Weight Change & CV Data | HCP, captured 2026-11-13](https://trulicity.lilly.com/hcp/efficacy-weight#:~:text=52%2Dweek%20A1C%20change%20from%20baseline%20results%20are%20exploratory.)

## Comparative studies

<a id="trulicity-vs-metformin"></a>

### Trulicity vs metformin: how do A1C results compare as monotherapy?

Applies to: Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

> “In a double-blind trial with primary endpoint at 26 weeks, 807 adult patients inadequately treated with diet and exercise, or with diet and exercise and one antidiabetic agent used at submaximal dose, were randomized to TRULICITY 0.75 mg once weekly, TRULICITY 1.5 mg once weekly, or metformin 1500 to 2000 mg/day following a two-week washout. Seventy-five percent (75%) of the randomized population were treated with one antidiabetic agent at the screening visit. Most patients previously treated with an antidiabetic agent were receiving metformin (~90%) at a median dose of 1000 mg daily and approximately 10% were receiving a sulfonylurea.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=In%20a%20double%2Dblind%20trial%20with,10%25%20were%20receiving%20a%20sulfonylurea.)

> “Treatment with TRULICITY 0.75 mg and 1.5 mg once weekly resulted in reduction in HbA1c from baseline at 26-weeks (Table 4). The difference in observed effect size between TRULICITY 0.75 mg and 1.5 mg, respectively, and metformin excluded the pre-specified non-inferiority margin of 0.4%.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=from%20the%20US.-,Treatment%20with%20TRULICITY%200.75%20mg%20and%201.5%20mg%20once%20weekly,pre%2Dspecified%20non%2Dinferiority%20margin%20of%200.4%25.)

> “Table 4: Results at Week 26 in a Trial of TRULICITY as Monotherapy in Adult Patients with Type 2 Diabetes Mellitusa
>
> Abbreviation: HbA1c = hemoglobin A1c.
>
>
>
>
> a Intent-to-treat population. Last observation carried forward (LOCF) was used to impute missing data. Data post-onset of rescue therapy are treated as missing. At Week 26, primary efficacy was missing for 10%, 12% and 14% of individuals randomized to TRULICITY 0.75 mg, TRULICITY 1.5 mg and metformin, respectively.
>
>
>
>
> b Least-squares mean adjusted for baseline value and other stratification factors.
>
>
>
>
> ‡ Patients included in the analysis are a subset of the ITT population that had at least one post-baseline assessment. The primary analysis included 265 individuals in each of the treatment arms.
>
>
> 	26-Week Primary Time Point
> TRULICITY 0.75 mg	TRULICITY 1.5 mg	Metformin
> 1500-2000 mg
> Intent-to-Treat (ITT) Population (N)‡	270	269	268
> HbA1c (%) (Mean)
> Baseline	7.6	7.6	7.6
> Change from baselineb	-0.7	-0.8	-0.6
> Fasting Serum Glucose (mg/dL) (Mean)
> Baseline	161	164	161
> Change from baselineb	-26	-29	-24
> Body Weight (kg) (Mean)
> Baseline	91.8	92.7	92.4
> Change from baselineb	-1.4	-2.3	-2.2”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=Table%204%3A%20Results%20at%20Week,%2D2.2)

Note: Table 4 columns are TRULICITY 0.75 mg, 1.5 mg, and metformin 1500-2000 mg, in that order.

<a id="trulicity-vs-sitagliptin"></a>

### Trulicity vs sitagliptin: which lowers A1C more with metformin?

Applies to: Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

> “In this placebo-controlled, double-blind trial with primary endpoint at 52 weeks, 972 adult patients were randomized to placebo, TRULICITY 0.75 mg once weekly, TRULICITY 1.5 mg once weekly, or sitagliptin 100 mg/day (after 26 weeks, patients in the placebo treatment group received blinded sitagliptin 100 mg/day for the remainder of the trial), all as add-on to metformin.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=In%20this%20placebo%2Dcontrolled%2C%20double%2Dblind%20trial,all%20as%20add%2Don%20to%20metformin.)

> “Treatment with TRULICITY 0.75 mg and 1.5 mg once weekly resulted in a statistically significant reduction in HbA1c compared to placebo (at 26 weeks) and compared to sitagliptin (at 26 and 52 weeks), all in combination with metformin (Table 5 and Figure 3).”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=and%20sitagliptin%2C%20respectively.-,Treatment%20with%20TRULICITY%200.75%20mg%20and%201.5%20mg%20once%20weekly,%28Table%205%20and%20Figure%203%29.)

> “Table 5: Results at Week 52 of TRULICITY Compared to Sitagliptin used as Add-On to Metformin in Adult Patients with Type 2 Diabetes Mellitusa
>
> Abbreviations: HbA1c = hemoglobin A1c.
>
>
>
>
> a All ITT patients randomized after the dose-finding portion of the trial. Last observation carried forward (LOCF) was used to impute missing data. At Week 52 primary efficacy was missing for 15%, 19%, and 20% of individuals randomized to TRULICITY 0.75 mg, TRULICITY 1.5 mg and sitagliptin, respectively.
>
>
>
>
> b Least-squares (LS) mean adjusted for baseline value and other stratification factors.
>
>
>
>
> ‡ Patients included in the analysis are a subset of the ITT population that had at least one post-baseline assessment. The primary analysis included 276, 277, and 270 individuals randomized to TRULICITY 0.75 mg, TRULICITY 1.5 mg and sitagliptin, respectively.
>
>
>
>
> †† Multiplicity adjusted 1-sided p-value <0.001, for superiority of TRULICITY compared to sitagliptin, assessed only for HbA1c.
>
>
>
>
> ## p<0.001 TRULICITY compared to sitagliptin, assessed only for HbA1c <7.0%.
>
>
> 	52-Week Primary Time Point
> TRULICITY
> 0.75 mg	TRULICITY
> 1.5 mg	Sitagliptin
> 100 mg
> Intent-to-Treat (ITT) Population (N)‡	281	279	273
> HbA1c (%) (Mean)
> Baseline	8.2	8.1	8.0
> Change from baselineb	-0.9	-1.1	-0.4
> Difference from sitagliptinb (95% CI)	-0.5 (-0.7, -0.3)††	-0.7 (-0.9, -0.5)††	-
> Percentage of patients HbA1c <7.0%	49##	59##	33
> Fasting Plasma Glucose (mg/dL) (Mean)
> Baseline	174	173	171
> Change from baselineb	-30	-41	-14
> Difference from sitagliptinb (95% CI)	-15 (-22, -9)	-27 (-33, -20)	-
> Body Weight (kg) (Mean)
> Baseline	85.5	86.5	85.8
> Change from baselineb	-2.7	-3.1	-1.5
> Difference from sitagliptinb (95% CI)	-1.2 (-1.8, -0.6)	-1.5 (-2.1, -0.9)	-”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=Table%205%3A%20Results%20at%20Week,%2D1.5%20%28%2D2.1%2C%20%2D0.9%29)

Note: Table 5 columns are TRULICITY 0.75 mg, 1.5 mg, and sitagliptin 100 mg, in that order.

<a id="trulicity-vs-insulin-glargine"></a>

### Trulicity vs insulin glargine: how do A1C and weight compare?

Applies to: Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

> “In this open-label comparator trial (double-blind with respect to TRULICITY dose assignment) with primary endpoint at 52 weeks, 807 adult patients were randomized to and received TRULICITY 0.75 mg once weekly, TRULICITY 1.5 mg once weekly, or insulin glargine once daily, all as add-on to maximally tolerated doses of metformin and glimepiride.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=In%20this%20open%2Dlabel%20comparator%20trial,doses%20of%20metformin%20and%20glimepiride.)

> “Only 24% of patients were titrated to goal at the 52-week primary endpoint.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=Only%2024%25%20of%20patients%20were,at%20the%2052%2Dweek%20primary%20endpoint.)

> “Treatment with TRULICITY once weekly resulted in a reduction in HbA1c from baseline at 52 weeks when used in combination with metformin and sulfonylurea (Table 10). The difference in observed effect size between TRULICITY 0.75 mg and 1.5 mg, respectively, and glargine in this trial excluded the pre-specified non-inferiority margin of 0.4%.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=Treatment%20with%20TRULICITY%20once%20weekly,pre%2Dspecified%20non%2Dinferiority%20margin%20of%200.4%25.)

> “Table 10: Results at Week 52 of TRULICITY Compared to Insulin Glargine, Both as Add-on to Metformin and Sulfonylurea in Adult Patients with Type 2 Diabetes Mellitusa
>
> Abbreviations: HbA1c = hemoglobin A1c.
>
>
>
>
> a Intent-to-treat population. Last observation carried forward (LOCF) was used to impute missing data. Data post-onset of rescue therapy are treated as missing. At Week 52, primary efficacy was missing for 17%, 13% and 12% of individuals randomized to TRULICITY 0.75 mg, TRULICITY 1.5 mg and glargine, respectively.
>
>
>
>
> b Least-squares (LS) mean adjusted for baseline value and other stratification factors.
>
>
>
>
> ‡ Patients included in the analysis are a subset of the ITT population that had at least one post-baseline assessment. The primary analysis included 267, 263 and 259 individuals randomized to TRULICITY 0.75 mg, TRULICITY 1.5 mg, and glargine, respectively.
>
>
> 	52-Week Primary Time Point
> TRULICITY
> 0.75 mg	TRULICITY
> 1.5 mg	Insulin Glargine
> Intent-to-Treat (ITT) Population (N)‡	272	273	262
> HbA1c (%) (Mean)
> Baseline	8.1	8.2	8.1
> Change from baselineb	-0.8	-1.1	-0.6
> Fasting Serum Glucose (mg/dL) (Mean)
> Baseline	161	165	163
> Change from baselineb	-16	-27	-32
> Difference from insulin glargineb (95% CI)	16 (9, 23)	5 (-2, 12)	-
> Body Weight (kg) (Mean)
> Baseline	86.4	85.2	87.6
> Change from baselineb	-1.3	-1.9	1.4
> Difference from insulinb (95% CI)	-2.8 (-3.4, -2.2)	-3.3 (-3.9, -2.7)	-”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=Table%2010%3A%20Results%20at%20Week,%2D3.3%20%28%2D3.9%2C%20%2D2.7%29)

Note: Table 10 columns are TRULICITY 0.75 mg, 1.5 mg, and insulin glargine, in that order. All arms were add-on to maximally tolerated metformin and glimepiride.

<a id="trulicity-vs-exenatide"></a>

### Trulicity vs exenatide: how do A1C results compare?

Applies to: Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

> “In this placebo-controlled trial with primary endpoint at 26 weeks, 976 adult patients were randomized to and received placebo, TRULICITY 0.75 mg once weekly, TRULICITY 1.5 mg once weekly, or exenatide 10 mcg BID, all as add-on to maximally tolerated doses of metformin (≥1500 mg per day) and pioglitazone (up to 45 mg per day).”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=In%20this%20placebo%2Dcontrolled%20trial%20with,to%2045%20mg%20per%20day%29.)

> “Treatment with TRULICITY 0.75 mg and 1.5 mg once weekly resulted in a statistically significant reduction in HbA1c compared to placebo (at 26 weeks) and compared to exenatide at 26 weeks (Table 8 and Figure 5).”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=in%20the%20US.-,Treatment%20with%20TRULICITY%200.75%20mg%20and%201.5%20mg%20once%20weekly,%28Table%208%20and%20Figure%205%29.)

> “Table 8: Results at Week 26 of TRULICITY Compared to Placebo and Exenatide, All as Add-On to Metformin and Thiazolidinedione in Adult Patients with Type 2 Diabetes Mellitusa
>
> Abbreviations: BID = twice daily; HbA1c = hemoglobin A1c.
>
>
>
>
> a Intent-to-treat population. Last observation carried forward (LOCF) was used to impute missing data. Data post-onset of rescue therapy are treated as missing. At Week 26, primary efficacy was missing for 23%, 10%, 7% and 12% of individuals randomized to placebo, TRULICITY 0.75 mg, TRULICITY 1.5 mg, and exenatide, respectively.
>
>
>
>
> b Least-squares (LS) mean adjusted for baseline value and other stratification factors.
>
>
>
>
> ‡ Patients included in the analysis are a subset of the ITT population that had at least one post-baseline assessment. The primary analysis included 119, 269, 271 and 266 individuals randomized to placebo, TRULICITY 0.75 mg, TRULICITY 1.5 mg, and exenatide, respectively.
>
>
>
>
> ‡‡ Multiplicity adjusted 1-sided p-value <0.001, for superiority of TRULICITY compared to placebo, assessed only for HbA1c.
>
>
>
>
> †† Multiplicity adjusted 1-sided p-value <0.001, for superiority of TRULICITY compared to exenatide, assessed only for HbA1c.
>
>
>
>
> ** p<0.001 TRULICITY compared to placebo, assessed only for HbA1c <7.0%.
>
>
>
>
> ## p<0.001 TRULICITY compared to exenatide, assessed only for HbA1c <7.0%.
>
>
> 	26-Week Primary Time Point
> Placebo	TRULICITY
> 0.75 mg	TRULICITY
> 1.5 mg	Exenatide
> 10 mcg BID
> Intent-to-Treat (ITT) Population (N)‡	141	280	279	276
> HbA1c (%) (Mean)
> Baseline	8.1	8.1	8.1	8.1
> Change from baselineb	-0.5	-1.3	-1.5	-1.0
> Difference from placebob (95% CI)	-	-0.8 (-1.0, -0.7)‡‡	-1.1 (-1.2, -0.9)‡‡	-
> Difference from exenatideb (95% CI)	-	-0.3 (-0.4, -0.2)††	-0.5 (-0.7, -0.4)††	-
> Percentage of patients HbA1c <7.0%	43	66**, ##	78**, ##	52
> Fasting Serum Glucose (mg/dL) (Mean)
> Baseline	166	159	162	164
> Change from baselineb	-5	-34	-42	-24
> Difference from placebob (95% CI)	-	-30 (-36, -23)	-38 (-45, -31)	-
> Difference from exenatideb (95% CI)	-	-10 (-15, -5)	-18 (-24, -13)	-
> Body Weight (kg) (Mean)
> Baseline	94.1	95.5	96.2	97.4
> Change from baselineb	1.2	0.2	-1.3	-1.1
> Difference from placebob (95% CI)	-	-1.0 (-1.8, -0.3)	-2.5 (-3.3, -1.8)	-
> Difference from exenatideb (95% CI)	-	1.3 (0.6, 1.9)	-0.2 (-0.9, 0.4)	-”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=Table%208%3A%20Results%20at%20Week,%2D0.2%20%28%2D0.9%2C%200.4%29)

Note: Table 8 columns are placebo, TRULICITY 0.75 mg, TRULICITY 1.5 mg, and exenatide 10 mcg twice daily, in that order.

## Cardiovascular outcomes

<a id="trulicity-rewind-mace"></a>

### Does Trulicity lower the risk of heart attack, stroke, or CV death (REWIND)?

Applies to: Reduction of the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors

> “The REWIND trial (NCT01394952) was a multi-national, multi-center, randomized, placebo-controlled, double-blind trial. In this trial, 9901 adult patients with type 2 diabetes mellitus and established cardiovascular (CV) disease or multiple cardiovascular risk factors were randomized to TRULICITY 1.5 mg or placebo both added to standard of care. The median follow-up duration was 5.4 years. The primary endpoint was the time to the first occurrence of a composite 3-component Major Adverse Cardiovascular Events (MACE) outcome, which included CV death, non-fatal myocardial infarction (MI), and non-fatal stroke.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=The%20REWIND%20trial%20%28NCT01394952%29%20was,infarction%20%28MI%29%2C%20and%20non%2Dfatal%20stroke.)

> “For the primary analysis, a Cox proportional hazards model was used to test for superiority. Type I error was controlled across multiple tests. TRULICITY significantly reduced the risk of first occurrence of primary composite endpoint of CV death, non-fatal MI, or non-fatal stroke (HR: 0.88, 95% CI 0.79, 0.99).”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=For%20the%20primary%20analysis%2C%20a,0.88%2C%2095%25%20CI%200.79%2C%200.99%29.)

> “Table 14: Treatment Effect for MACE and the Individual Components in the REWIND Trial, Median Trial Observation Time of 5.4 years in Adult Patients with Type 2 Diabetes Mellitusa
>
> a All randomized patients.
>
>
>
>
> b Cox-proportional hazards model with treatment as a factor. Type I error was controlled for the primary and secondary endpoints.
>
>
>
>
> c p=0.026 for superiority (2-sided).
>
>
>
>
> d Number and percentage of patients with events.
>
>
>
>
> e Results for components of MACE, fatal and non-fatal stroke, and fatal and non-fatal MI are listed descriptively for supportive purposes. No statistical significance should be inferred since these CIs are not adjusted for multiplicity.
>
>
> Time to First Occurrence of:	TRULICITY
> N=4949	Placebo
> N=4952	Hazard Ratio
> (95% CI)b
> Composite of non-fatal myocardial infarction, non-fatal stroke, cardiovascular death (MACE)d	594 (12.0%)	663 (13.4%)	0.88 (0.79, 0.99)c
>      Cardiovascular deathd,e	317 (6.4%)	346 (7.0%)	0.91 (0.78, 1.06)
>      Non-fatal myocardial infarctiond,e	205 (4.1%)	212 (4.3%)	0.96 (0.79, 1.16)
>      Non-fatal stroked,e	135 (2.7%)	175 (3.5%)	0.76 (0.61, 0.95)
> Fatal or non-fatal myocardial infarctiond,e	223 (4.5%)	231 (4.7%)	0.96 (0.79, 1.15)
> Fatal or non-fatal stroked,e	158 (3.2%)	205 (4.1%)	0.76 (0.62, 0.94)”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=Table%2014%3A%20Treatment%20Effect%20for,0.76%20%280.62%2C%200.94%29)

Note: Table 14 columns are TRULICITY (N=4949), placebo (N=4952), and the hazard ratio with its 95% CI.

<a id="trulicity-rewind-death"></a>

### Did Trulicity lower the risk of death in REWIND?

Applies to: Reduction of the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors

> “Vital status was available for 99.7% of patients in the trial. A total of 1128 deaths were recorded during the REWIND trial. A majority of the deaths in the trial were adjudicated as CV deaths, and non-CV deaths were comparable between the treatment groups (4.4% in patients treated with TRULICITY and 5.0% in patients treated with placebo). There were 536 all-cause deaths (10.8%) in the dulaglutide group compared to 592 deaths (12.0%) in the placebo group.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=Vital%20status%20was%20available%20for,%2812.0%25%29%20in%20the%20placebo%20group.)

> “Cardiovascular deathd,e	317 (6.4%)	346 (7.0%)	0.91 (0.78, 1.06)”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=Cardiovascular%20deathd%2Ce,0.91%20%280.78%2C%201.06%29)

> “e Results for components of MACE, fatal and non-fatal stroke, and fatal and non-fatal MI are listed descriptively for supportive purposes. No statistical significance should be inferred since these CIs are not adjusted for multiplicity.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=e%20Results%20for%20components%20of,are%20not%20adjusted%20for%20multiplicity.)

Note: The second passage is the cardiovascular death row of Table 14: TRULICITY, placebo, and the hazard ratio with its 95% CI. The Prescribing Information reports all-cause deaths as counts without a hazard ratio or statistical test; the cardiovascular death row is descriptive (footnote e), and its 95% CI includes 1.

<a id="trulicity-rewind-design"></a>

### Who was enrolled in the Trulicity REWIND cardiovascular outcomes trial?

Applies to: Reduction of the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors

> “Multicenter, randomized, double-blind, placebo-controlled, event-driven trial designed to assess whether once-weekly Trulicity 1.5 mg safely reduces the incidence of cardiovascular (CV) outcomes compared to placebo in adult patients with type 2 diabetes with and without CVD
> Key inclusion criteria: Established or newly detected type 2 diabetes with an A1C ≤9.5%; stable dose of up to 2 oral glucose-lowering drugs with or without basal insulin; BMI ≥23 kg/m2; age ≥50 years with established clinical vascular disease<sup>*</sup>, OR age ≥55 years and subclinical<sup>†</sup> vascular disease, OR age ≥60 years and at least 2 or more CV risk factors<sup>‡</sup>
> Key exclusion criteria: Uncontrolled diabetes; severe hypoglycemia in preceding year; coronary or cerebrovascular event in preceding 2 months; plans to revascularize; estimated glomerular filtration rate (eGFR) <15 mL/min/1.73 m<sup>2</sup>; on dialysis; gastric bypass or emptying abnormality; prior pancreatitis; liver disease; family or personal history of C-cell hyperplasia, medullary thyroid cancer, multiple endocrine neoplasia (MEN) 2A or 2B, or calcitonin ≥20 pg/mL; unwilling to stop GLP-1 RA, dipeptidyl peptidase-4 (DPP-4) inhibitor, or weight loss drug; cancer within preceding 5 years; possible pregnancy; life expectancy <1 year
> 9901 patients were randomized to receive Trulicity 1.5 mg or same volume of placebo in addition to standard of care treatments such as oral antidiabetic treatments, insulin, and antihypertensive, antiplatelet, and lipid-lowering therapies; patients were assessed every 6 months until 1200 confirmed primary outcomes had accrued
> Primary outcome was the first occurrence of the composite of either nonfatal MI, nonfatal stroke, or CV death (MACE-3). All outcomes occurring on or after randomization were included in analysis; Kaplan-Meier estimates were used to generate cumulative risks and Cox proportional hazard models were used to determine the effect of intervention on the outcome and to estimate HR and 95% CIs”

Source: [TRULICITY: Trulicity for Cardiovascular | REWIND Trial, captured 2026-11-13](https://trulicity.lilly.com/hcp/efficacy-weight/cardiovascular-disease#:~:text=Multicenter%2C%20randomized%2C%20double%2Dblind%2C%20placebo%2Dcontrolled%2C%20event%2Ddriven,estimate%20HR%20and%2095%25%20CIs)

> “<sup>*</sup>History of myocardial infarction (MI), ischemic stroke, revascularization, hospitalization for unstable angina with concordant new ischemic electrocardiogram changes, or a positive stress test with concordant imaging.<sup>4</sup>
> <sup>†</sup>Myocardial ischemia, coronary, carotid, or lower extremity artery stenosis exceeding 50%, ankle to brachial index <0.9, hypertension with left ventricular hypertrophy, eGFR <60 mL/min per 1.73m<sup>2</sup>, or albuminuria.<sup>4</sup>
> <sup>‡</sup>Tobacco use, dyslipidemia, hypertension, or abdominal obesity.<sup>2</sup>”

Source: [TRULICITY: Trulicity for Cardiovascular | REWIND Trial, captured 2026-11-13](https://trulicity.lilly.com/hcp/efficacy-weight/cardiovascular-disease#:~:text=of%20myocardial%20infarction%20%28MI%29%2C%20ischemic,use%2C%20dyslipidemia%2C%20hypertension%2C%20or%20abdominal)

> “At baseline, demographic and disease characteristics were balanced between treatment groups. Patients had a mean age of 66 years; 46% were female; race: White, Black, and Asian were 76%, 7%, and 4%, respectively.
>
> The median baseline HbA1c was 7.2%. The mean duration of type 2 diabetes was 10.5 years and the mean BMI was 32.3 kg/m2.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=At%20baseline%2C%20demographic%20and%20disease,mean%20BMI%20was%2032.3%20kg%2Fm2.)

## Related pages
- [Medical information: Trulicity (dulaglutide): Type 2 diabetes](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes)
- [Indication](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/safety)
- [Specific populations](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/guidelines)
